These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9624582)

  • 1. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
    Salard D; Kuzel TM; Samuelson E; Rosen S; Bakouche O
    J Clin Immunol; 1998 May; 18(3):223-34. PubMed ID: 9624582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
    Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
    Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
    Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
    Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
    Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
    Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAB
    Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
    Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4.
    Jabara HH; Vercelli D; Schneider LC; Williams DP; Genbauffe FS; Poisson LR; Waters CA; Geha RS
    J Allergy Clin Immunol; 1995 Apr; 95(4):893-900. PubMed ID: 7722171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
    Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
    Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.
    Walz G; Zanker B; Murphy JR; Strom TB
    Transplantation; 1990 Jan; 49(1):198-201. PubMed ID: 2301012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production.
    Pullerits T; Lundin S; Dahlgren U; Telemo E; Hanson LA; Lötvall J
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):843-9. PubMed ID: 10329818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells.
    Zhang LJ; Waters CA; Poisson LR; Estis LF; Crumpacker CS
    J Infect Dis; 1997 Apr; 175(4):790-4. PubMed ID: 9086131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.
    Walz G; Zanker B; Brand K; Waters C; Genbauffe F; Zeldis JB; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9485-8. PubMed ID: 2594781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
    Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
    Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
    Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
    Abrams JT; Ghosh SK; DeFreitas E
    Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.
    Zhang L; Waters C; Nichols J; Crumpacker C
    J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.
    Gottlieb SL; Gilleaudeau P; Johnson R; Estes L; Woodworth TG; Gottlieb AB; Krueger JG
    Nat Med; 1995 May; 1(5):442-7. PubMed ID: 7585092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
    Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
    J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.